ALKERMES PUBLIC LIMITED COMPANY
ALKS · NASDAQ
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
ESG Scores
Overall ESG5.7
Environmental5.7
Social3.0
Governance7.3
Gender Diversity
Female Directors0.2727%
Women in Workforce0.48%
CEO GenderMale
Market Data
Price$34.53+0.77 (+2.27%)
Market Cap$5.74B
P/E Ratio23.75
EPS$—
52W High$36.48
52W Low$25.17
Beta0.29